Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

Breast Cancer Res · 2010 · PMC2949634 · PMID 20615243

Europe PMC DOI

hedged sentences

0.0000

closest p · 0.0× alpha

0.0640

boldest claim

The sentences

highly significantP < 0.00001actually significant

All eligible cases (1,300 cases) Univariate analysis of all cases with complete Mammostrat ® data irrespective of ER status, nodal status or treatment showed a highly significant association between Mammostrat ® score and DRFS (Figure 2b ), between score and RFS (Figure S1D in Additional file 1 ), and between score and OS (all P < 0.00001; Figure S2D in Additional file 1 ).

also in 132,142 other papers

a trend towards significanceP = 0.064so close (0.05 < p ≤ 0.1)

For RFS, the nodal status, tumor size, grade, menopausal status, multifocality and HER2 status were significant risk predictors with a trend towards significance for Mammostrat ® scores ( P = 0.064).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.